Clinical Trial Update: 68Ga-PSMA-0057 and 177Lu-PSMA-0057 in Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for two PSMA-targeted radiopharmaceuticals (68Ga-PSMA-0057 and 177Lu-PSMA-0057) being studied for PSMA-positive metastatic castration-resi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• 177Lu-PSMA-0057
• 68Ga-PSMA-0057

Snippet

Sponsor: Chengdu StarRay Therapeutics Co., Ltd | Conditions: Metastatic Castration-resistant Prostate Cancer (mCRPC) | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING